Loading…
← CockpitCompetitor Analysis › 300158.SZ Shanxi Zhendong Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Shanxi Zhendong Pharmaceutical Co., Ltd. Class A300158.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum neutral 40
Mkt cap
$641M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$7.36M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-18.6 pp
WACC 6.5%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥4.43
1D-1.3%
1W-9.2%
1M-12.6%
3M-22.7%
6M-22.3%
YTD-23.8%
1Y-36.1%
ATR %3.6%
52w lowhigh40.9% off high

What Shanxi Zhendong Pharmaceutical does

Employees: 3,695

Shanxi Zhendong Pharmaceutical at a glance

Size Shanxi Zhendong Pharmaceutical (300158.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $641M, the 3091st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.43 on 18 Nov 2026.

Performance Over six months the shares fell 22.3%, against -19.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 27.5% over the last twelve months (peer median +0.5%); the operating margin is -25.0% (peer median 9.5%).

Valuation It trades at 1.8× enterprise value to sales against a peer median of 3.0× (5th cheapest of 20).

Capital Return on invested capital runs 18.6 points below its cost of capital (6.5% WACC).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 81300158.SZ 80
Six months, rebased to 100: Shanxi Zhendong Pharmaceutical against the median of its 20 peers (local-currency closes).

Shanxi Zhendong Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.10BCN¥2.77BCN¥2.96BCN¥3.61BCN¥3.69B
Revenue growth—-6%-18%-2%—
Gross profitCN¥1.05BCN¥1.30BCN¥1.32BCN¥1.73BCN¥1.72B
EBITDAn/a-CN¥177M-CN¥517MCN¥24.7MCN¥63.4M
Net income-CN¥494M-CN¥301M-CN¥1.33B-CN¥44.0M-CN¥51.3M
Free cash flow-CN¥304M-CN¥627M-CN¥401M-CN¥306MCN¥18.3M
Capital expenditureCN¥133MCN¥179MCN¥298MCN¥116MCN¥146M
Total debtCN¥290MCN¥231MCN¥72.7MCN¥121MCN¥56.1M

Quarterly statements and history in the cockpit →

Shanxi Zhendong Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%0025620775300261300039301507600488AVBP00264430079128770024126032620460603669317450PHN002219APN002826000756300158.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shanxi Zhendong Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%2.5×5×7.5×00256207753002613000393015076004880026443007910024126032620460603669317450PHN002219APN002826000756300158.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanxi Zhendong Pharmaceutical is the large dot.

Shanxi Zhendong Pharmaceutical competitors and peer comparison

How Shanxi Zhendong Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanxi Zhendong Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300158.SZPeer medianRank in peer set
1-month return-12.6%-9.8%7th lowest of 21
6-month return-22.3%-19.9%9th lowest of 21
Distance from 52-week high-40.9%-44.4%10th highest of 21
Revenue growth (TTM)-27.5%+0.5%lowest of 20
Operating margin-25.0%9.5%2nd lowest of 21
EV / Sales1.8×3.0×5th cheapest of 20
ROIC minus cost of capital-18.6 pp+0.4 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
TSI 603262.SSChina$842M-46%+3%14%4.6×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%2.1×n/an/a
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%5.6×4.7%+18.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%2.9×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%4.6×24.6%+38.5%
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%2.9×0.4%+1.0%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%0.9×0.5%+7.9%

Questions

Which companies are Shanxi Zhendong Pharmaceutical's closest peers?
The cockpit's peer set: Brother Enterprises (002562.SZ), CK Life Sciences International (Holdings) (0775.HK), ABA Chemicals (300261.SZ), Shanghai Kaibao Pharmaceutical (300039.SZ), Hangzhou Minsheng Healthcare (301507.SZ), Tianjin Tianyao Pharmaceuticals (600488.SS), ArriVent BioPharma (AVBP), Lanzhou Foci Pharmaceutical (002644.SZ).
Is Shanxi Zhendong Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.8× against a peer median of 3.0×, 5th cheapest of 20 in its peer set.
How has Shanxi Zhendong Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -22.3% against -19.9% for the median peer; over one year -36.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.